GlassScriptPhysician profile
Paramvir S Sidhu
NPI 1124220116
$21,601.04
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,604 · 2020: $539 · 2021: $330 · 2022: $9,632 · 2023: $6,613 · 2024: $883.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,395 · Food and Beverage: $1,996 · Education: $79.99 · Travel and Lodging: $24.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,395.00 |
| Food and Beverage | $1,996.28 |
| Education | $79.99 |
| Travel and Lodging | $24.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $6,534.32 | 2019-2024 | Tavneos, Prolia, Enbrel |
| Novartis Pharmaceuticals Corporation | $3,971.90 | 2019-2024 | Cosentyx |
| Aurinia Pharma U.S., INC. | $3,697.31 | 2022-2023 | Lupkynis |
| Ucb, INC. | $3,690.99 | 2019-2024 | Bimzelx, Cimzia |
| Abbvie INC. | $858.44 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $500.26 | 2019-2023 | Uptravi, Opsumit |
| Lilly USA, LLC | $407.78 | 2019-2021 | |
| Genzyme Corporation | $315.00 | 2019-2020 | |
| Genentech USA, INC. | $246.66 | 2019 | |
| Horizon Therapeutics Plc | $224.75 | 2019 | |
| Janssen Biotech, INC. | $209.81 | 2019-2023 | Tremfya, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $208.39 | 2019-2020 | |
| Glaxosmithkline, LLC. | $203.88 | 2019-2023 | |
| Pfizer INC. | $184.00 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $111.76 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $104.48 | 2023 | Saphnelo |
| Takeda Pharmaceuticals U.S.A., INC. | $39.36 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $29.11 | 2020 | |
| Janssen Pharmaceuticals, INC | $20.22 | 2020 | |
| Radius Health, INC. | $18.65 | 2021 | |
| Shire North American Group INC | $12.23 | 2019 | |
| Medexus Pharma, INC. | $11.74 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paramvir Sidhu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.